Canada markets close in 6 hours 14 minutes
  • S&P/TSX

    18,745.70
    -233.31 (-1.23%)
     
  • S&P 500

    3,679.43
    -65.09 (-1.74%)
     
  • DOW

    29,523.39
    -403.55 (-1.35%)
     
  • CAD/USD

    0.7296
    +0.0019 (+0.26%)
     
  • CRUDE OIL

    90.15
    +1.70 (+1.92%)
     
  • BTC-CAD

    26,951.71
    -957.52 (-3.43%)
     
  • CMC Crypto 200

    447.70
    -7.33 (-1.61%)
     
  • GOLD FUTURES

    1,710.10
    -10.70 (-0.62%)
     
  • RUSSELL 2000

    1,734.35
    -18.16 (-1.04%)
     
  • 10-Yr Bond

    3.8920
    +0.0660 (+1.73%)
     
  • NASDAQ

    10,819.74
    -253.57 (-2.29%)
     
  • VOLATILITY

    30.63
    +0.11 (+0.36%)
     
  • FTSE

    6,997.40
    +0.13 (+0.00%)
     
  • NIKKEI 225

    27,116.11
    -195.19 (-0.71%)
     
  • CAD/EUR

    0.7475
    +0.0049 (+0.66%)
     

Don't be duped by doomsayers, JPMorgan says — the S&P will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce

·4 min read
Don't be duped by doomsayers, JPMorgan says — the S&P will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce
Don't be duped by doomsayers, JPMorgan says — the S&P will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce

Looking at the S&P 500 right now, you might be convinced the stock market is destined for doom in 2022.

The benchmark index rose nearly 27% last year. This year, it’s already down 22%. Plenty of stocks are deep into correction territory.

Yet JPMorgan’s global head of equity macro research, Dubravko Lakos, sees a major rebound on the horizon.

“People are basically positioned for a recession. Our base case is that this is not going to be a recession in the next 12 months,” Lakos told CNBC earlier this month. “And we think from that angle the portfolios are wrong footed.”

Lakos reiterated a year-end price target of 4,900 for the S&P 500. Since the index sits at 3,736 today, his target implies a potential upside of around 31%.

If you’re aligned with Lakos and are looking ahead to a potential reversal, here’s three stocks JPMorgan finds particularly attractive right now.

Don't miss

  • Bill Gates says crypto and NFTs are a fool's game — here's the surprising thing he buys instead

  • Mitt Romney says a billionaire tax will trigger demand for these two assets — get in now before the super-rich swarm

  • Eager to escape the dismal stock market? Unfortunately, “cash is not a safe investment,” says Ray Dalio, founder of the world’s largest hedge fund. “It’s not a safe place because it will be taxed by inflation.” With the consumer price index hitting a 40-year high of 8.6% in May, you’ll need to get creative to find strong returns.

Smartsheet (SMAR)

This work-management platform helps companies implement, organize and automate their processes. Smartsheet says its application is used by more than 80% of Fortune 500 companies.

And business is growing. In the fiscal quarter ended April 30, revenue surged 44% year over year to $168.3 million, driven by a 44% increase in subscription revenue.

Notably, Smartsheet’s dollar-based net retention rate was a solid 133%.

But the stock is far from being a hot commodity. Year to date, shares are down a painful 61%. That could give contrarian investors something to think about.

Last week, JPMorgan analyst Pinjalim Bora reiterated an “overweight” rating on Smartsheet. While Bora also lowered his price target from $80 to $58, the new target is still 96% above where the stock sits today.

Microsoft (MSFT)

Tech stocks are getting dumped in this market downturn. Even mega-cap behemoths like Microsoft aren’t immune to the bearish sentiment.

The stock has tumbled 26% in 2022.

But business remains on the right track. In the March quarter, Microsoft’s revenue grew 18% year over year to $49.4 billion. Adjusted earnings came in at $2.22 per share, up 9% from the year-ago period.

The tech gorilla is also returning a massive amount of cash to investors. For the quarter, Microsoft’s dividends and share buybacks totaled $12.4 billion, representing a 25% increase year over year.

JPMorgan analyst Mark Murphy recently raised his price target on Microsoft to $320 while maintaining a “buy” rating. That implies a potential upside of 30%.

Eli Lilly (LLY)

This American pharmaceutical giant commands more than $270 billion in market cap, with products marketed in 120 countries around the world.

Unlike the other two names on this list, Eli Lilly is not a beaten-down stock.

In Q1, Eli Lilly delivered 15% revenue growth, driven by a 20% growth in volume. The company paid nearly $900 million in dividends and spent $1.5 billion on buybacks during the quarter.

Shares are actually up 7% so far in 2022, and JPMorgan expects the trend to continue.

On June 1, analyst Chris Schott reiterated an “overweight” rating on Eli Lilly while raising his price target from $340 to $355.

Considering that shares trade at around $291 apiece right now, the new price target implies a potential upside of 22%.

What to read next

This article provides information only and should not be construed as advice. It is provided without warranty of any kind.